{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-09-11&questionFirstAnswered.=2015-09-16T15%3A23%3A43.363Z", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?date=2015-09-11&questionFirstAnswered.=2015-09-16T15%3A23%3A43.363Z", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-09-11&questionFirstAnswered.=2015-09-16T15%3A23%3A43.363Z&_metadata=all", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-09-11&_page=0&questionFirstAnswered.=2015-09-16T15%3A23%3A43.363Z", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-09-11&questionFirstAnswered.=2015-09-16T15%3A23%3A43.363Z", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-09-11&questionFirstAnswered.=2015-09-16T15%3A23%3A43.363Z", "items" : [{"_about" : "http://data.parliament.uk/resources/418452", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/418452/answer", "answerText" : {"_value" : "<p>NHS England has advised that the mechanisms for appeal are as set out in Appendix G, section 11 of the Cancer Drugs Fund Standard Operating Procedures which are published on NHS England\u2019s website at:<\/p><p> <\/p><p> <\/p><p> <\/p><p><a href=\"http://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop-2015-16.pdf\" target=\"_blank\">www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop-2015-16.pdf<\/a><\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-09-16T15:23:43.363Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer Drugs Fund"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what mechanisms there are for appeal against NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
      }
      , "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
      , "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
      ], "uin" : "10092"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}